Pre-made Vixarelimab benchmark antibody ( Whole mAb, anti-OSMR therapeutic antibody, Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Vixarelimab biosimilar, Whole mAb, Anti-OSMR Antibody: Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vixarelimab is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-623-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Vixarelimab biosimilar, Whole mAb, Anti-OSMR Antibody: Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 therapeutic antibody
INN Name	Vixarelimab
Target	OSMR
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4-G1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	Kiniksa Pharmaceuticals
Conditions Approved	na
Conditions Active	Prurigo nodularis;Pruritus;Atopic dermatitis
Conditions Discontinued	na
Development Tech	na